Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

0.6100
+0.02524.31%
Post-market: 0.61000.00000.00%19:07 EDT
Volume:146.17K
Turnover:91.88K
Market Cap:8.37M
PE:-0.29
High:0.6614
Open:0.5990
Low:0.5990
Close:0.5848
52wk High:7.95
52wk Low:0.5450
Shares:13.71M
Float Shares:12.75M
Volume Ratio:0.78
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0700
EPS(LYR):-2.0700
ROE:-1599.81%
ROA:-77.74%
PB:-7.35
PE(LYR):-0.29

Loading ...

Vivos Therapeutics Earnings Call: Growth Meets Cash Strain

TIPRANKS
·
May 22

Vivos Therapeutics reports Q1 EPS (52c), consensus (45c)

TIPRANKS
·
May 21

Vivos Therapeutics Q1 revenue jumps, driven by SCN acquisition

Reuters
·
May 21

Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate

Benzinga
·
May 21

Vivos Therapeutics Q1 FY26 net loss more than doubles to $7.8 million; revenue rises 70% to $5.1 million

Reuters
·
May 21

BRIEF-Vivos Therapeutics Q1 Net Income USD -7.751 Million

Reuters
·
May 21

Vivos Therapeutics Q1 Gross Profit USD 3.059 Million

THOMSON REUTERS
·
May 21

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

THOMSON REUTERS
·
May 21

Vivos Therapeutics Delays Quarterly Filing

TIPRANKS
·
May 16

Vivos Therapeutics delays Q1 10-Q filing, seeks SEC extension

Reuters
·
May 16

Vivos Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
May 12

Vivos Therapeutics Faces Nasdaq Listing Compliance Challenges

TIPRANKS
·
Apr 23

Vivos Therapeutics gets Nasdaq notice for failing minimum stockholders’ equity rule

Reuters
·
Apr 23

Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Apr 22

Vivos Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 17

Analysts Conflicted on These Healthcare Names: Vivos Therapeutics (VVOS), Certara (CERT) and Option Care Health (OPCH)

TIPRANKS
·
Apr 17

Vivos Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright

TIPRANKS
·
Apr 17

Vivos Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $2.5 From $7

THOMSON REUTERS
·
Apr 17

Vivos Therapeutics Balances Growth Hopes With Cash Strain

TIPRANKS
·
Apr 17

Vivos Therapeutics Q4 EPS $(0.58) Misses $(0.48) Estimate, Sales $3.824M Miss $6.447M Estimate

Benzinga
·
Apr 16